
Despite its high incidence and mortality risk, there is no evidence‐based non‐ischaemic cardiogenic shock (CS) treatment. Therefore, this study aimed to evaluate mechanical circulatory support (MCS) use for non‐ischaemic CS treatment. Patients treated with MCS presented with more severe CS (37% vs 23% deteriorating CS, 30% vs 25% in extremis CS) and had a lower left ventricular ejection fraction at baseline (21% vs 25%). In patients with non‐ischaemic CS, MCS use was associated with lower 30‐day mortality compared to medical therapy but also with more complications.
Like
Save
Share